


Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: ?



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 101



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
 Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
 Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
 Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.10.sas

11DEC2014 00:01



Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 100



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01




Merck Serono
EMR 200125-001

Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 09:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: J



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01

Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01

Merck Serono
EMR 200125-001

Page 142 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: .



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 100111



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: - - - -



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01




Merck Serono
EMR 200125-001

Page 147 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.3.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: J



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1 0000



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: [REDACTED]



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01




Merck Serono
EMR 200125-001

Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⊖: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: ,



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: *



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1 1007



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01




Merck Serono
EMR 200125-001

Page 168 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



Ⓢ: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 15.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.3.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: ****



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01




Merck Serono
EMR 200125-001

Page 177 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01




Merck Serono
EMR 200125-001

Page 178 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01




Merck Serono
EMR 200125-001

Page 181 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: ?



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL_programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.3.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01




Merck Serono
EMR 200125-001

Page 184 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: .



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01




Merck Serono
EMR 200125-001

Page 185 of 216
Confidential

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.C.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: :



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
 Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
 Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
 15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



Ø: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: .



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: .



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.0.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old Formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number: J



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 09:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: 1



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: .



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
 Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
 Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
 Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
 15.4.2.10.sas

11DEC2014 00:01



Merck Serono
EMR 200125-001
Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number: .



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.3.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas


11DEC2014 00:01



Merck Serono
EMR 200125-001

Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale
(For Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.10.sas

11DEC2014 00:01



Figure 15.4.2.10 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (For Total T4 Values) (Safety Population)

Subject ID/Random Number:



⊘: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.
 Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
 Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
 15.4.2.10.sas

11DEC2014 00:01




Merck Serono
EMR 200125-001

Page 1 of 216
Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population;
 Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
 Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
 Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
 15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




0: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Merck Serono
EMR 200125-001
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
 Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
 Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
 Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure
 15.4.2.11.sas




Merck Serono
EMR 200125-001

Page 5 of 216
Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure
15.4.2.11.sas

Merck Serono
EMR 200125-001

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@: Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number: .



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas




Merck Serono
EMR 200125-001

Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
 Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
 Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
 Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
 15.4.2.11.sas




Merck Serono
EMR 200125-001

Page 9 of 216
Confidential

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number: 100




@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas



Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population;
Test: 600 µg (3*200 µg tablets) levothyroxine new formulation.
Reference: 600 µg (3*200 µg tablets) levothyroxine old formulation.
Source: Table 16.2.5.3

/project24/ep/blinded/e210899_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure
15.4.2.11.sas